دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Clinical outcomes after unprotected left main coronary artery occlusion: A retrospective multicentre cohort analysis
Marco Dürig MSc, Diego Arroyo MD, Marc Bedossa MD, Philippe Commeau MD, Stephane Fournier MD, PhD, Olivier Müller MD, PhD, Paul Barragan MD, Hervé Le Breton MD, PhD, Serban Puricel MD, Stéphane Cook MD, PhD
doi : 10.1002/ccd.30585
Unprotected left main coronary artery (ULMCA) occlusion is a rare and disastrous condition with scarce data on presentation and outcomes. Herein, we report data on patients presenting with acute coronary syndrome due to ULMCA occlusion at four different institutions.
Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial
Juan F. Iglesias MD, Olivier Muller MD, PhD, Sylvain Losdat PhD, Marco Roffi MD, David J. Kurz MD, Daniel Weilenmann MD, Christoph Kaiser MD, Dik Heg PhD, Stephan Windecker MD, Thomas Pilgrim MD, MSc
doi : 10.1002/ccd.30600
Ultrathin-strut biodegradable polymer sirolimus-eluting stents (BP-SES) are superior to thin-strut durable polymer everolimus-eluting stents (DP-EES) with respect to target lesion failure (TLF) at 2 years among patients with ST-segment elevation myocardial infarction (STEMI).
Impact of calcified nodule on target lesion failure after stent implantation in hemodialysis patients
Yutaka Matsuhiro MD, Daisuke Nakamura MD, Tomoharu Dohi MD, PhD, Takayuki Ishihara MD, Naotaka Okamoto MD, Isamu Mizote MD, PhD, Toshiaki Mano MD, PhD, Masami Nishino MD, PhD, Yasushi Sakata MD, PhD
doi : 10.1002/ccd.30599
Little is known about intravascular imaging predictors of cardiac events after drug-eluting stent (DES) implantation in hemodialysis (HD) patients. We aimed to reveal the association between calcified nodules (CN) and target lesion failure (TLF) in HD patients after DES implantation.
Serial quantitative angiographic study of target lumen enlargement after drug-coated balloon angioplasty for native coronary artery disease
Katsumi Ueno MD, PhD, Norihiko Morita MD, PhD, Yoshinobu Kojima MD, Hiroshi Takahashi PhD, Masayasu Esaki MD, PhD, Hiroki Kondo MD, Yu Ando MD, Mayu Yamada MD, Tai Kosokabe MD
doi : 10.1002/ccd.30598
Target lumen enlargement (TLE) or “late lumen enlargement� is often encountered after percutaneous coronary intervention (PCI) with drug-coated balloons (DCB). To date, the prognosis of coronary arterial lesions with or without TLE has not been clearly elucidated.
Distal versus conventional radial artery access for coronary catheterization: A systematic review and meta-analysis
Julien Feghaly MD, MPH, Kai Chen MD, Anamarys Blanco MD, Andres M. Pineda MD
doi : 10.1002/ccd.30602
The distal radial artery (DRA) access is an alternative to the conventional radial artery (CRA) access for coronary angiography and interventions and appears to be associated with reduced incidence of certain outcomes.
Impact of proximal cap ambiguity on the procedural techniques and outcomes of chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS-CTO Registry
Spyridon Kostantinis MD, Bahadir Simsek MD, Judit Karacsonyi MD, PhD, Athanasios Rempakos MD, Khaldoon Alaswad MD, Michael Megaly MD, Oleg Krestyaninov MD, Dmitrii Khelimskii MD, Dimitrios Karmpaliotis MD, PhD, Farouc A. Jaffer MD, PhD, Jaikirshan J. Khatri MD, Paul Poommipanit MD, Mitul P. Patel MD, Ehtisham Mahmud MD, Michael Koutouzis MD, Ioannis Tsiafoutis MD, Sevket Gorgulu MD, Basem Elbarouni MD, William Nicholson MD, Wissam Jaber MD, Stephane Rinfret MD, Nidal Abi Rafeh MD, Omer Goktekin MD, Ahmed M. ElGuindy MD, Salman S. Allana MD, Bavana V. Rangan BDS, MPH, Yader Sandoval MD, M. Nicholas Burke MD, Emmanouil S. Brilakis MD, PhD
doi : 10.1002/ccd.30580
Proximal cap ambiguity is a key parameter in the global chronic total occlusion (CTO) percutaneous coronary intervention (PCI) crossing algorithm.
Impact of lesion length on the outcomes of chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS-CTO registry
Athanasios Rempakos MD, Bahadir Simsek MD, Spyridon Kostantinis MD, Judit Karacsonyi MD, PhD, James W. Choi MD, Paul Poommipanit MD, Jaikirshan J. Khatri MD, Wissam Jaber MD, Stephane Rinfret MD, William Nicholson MD, Sevket Gorgulu MD, Farouc A. Jaffer MD, PhD, Raj Chandwaney MD, Michael Koutouzis MD, Ioannis Tsiafoutis MD, Khaldoon Alaswad MD, Oleg Krestyaninov MD, Dmitrii Khelimskii MD, Dimitrios Karmpaliotis MD, PhD, Barry F. Uretsky MD, Mitul P. Patel MD, Ehtisham Mahmud MD, Srinivasa Potluri MD, Bavana V. Rangan BDS, MPH, Olga C. Mastrodemos BA, Salman Allana MD, Yader Sandoval MD, Nicholas M. Burke MD, Emmanouil S. Brilakis MD, PhD
doi : 10.1002/ccd.30581
The impact of occlusion length on the procedural techniques and outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study.
Utilization of TandemHeart in cardiogenic shock: Insights from the THEME registry
Michael Megaly MD, MS, Chaun Gandolfo DO, Samer Zakhour MD, Mei Jiang PhD, Kristie Burgess PhD, Stanley Chetcuti MD, Michael Ragosta MD, Eric Adler MD, Andrew Coletti MD, Brian O'Neill MD, Khaldoon Alaswad MD, Mir B. Basir DO, FSCAI
doi : 10.1002/ccd.30582
TandemHeart has been demonstrated to improve hemodynamic and metabolic complications in cardiogenic shock (CS). Contemporary outcomes have not been reported.
Intraplaque wiring enables drug-coated balloons to be utilized for percutaneous recanalization of chronically occluded coronary arteries
Kazunori Terashita MD, Yoshihisa Shimada MD, PhD, FAPSIC, FJCC, FSCAI, Yuki Yamanaka MD, Yoshikazu Motohashi MD, PhD, Daisuke Tonomura MD, Kazuyasu Yoshitani MD, Masataka Yoshida MD, PhD, Takao Tsuchida MD, PhD, Hitoshi Fukumoto MD, PhD
doi : 10.1002/ccd.30596
This study aimed to determine whether drug-coated balloon (DCB) angioplasty following intraplaque wiring and the use of modified balloons is safe and effective in the percutaneous treatment of coronary chronic total occlusions (CTOs).
Impact of frailty on outcomes in acute ST-elevated myocardial infarctions undergoing percutaneous coronary intervention
Joseph Heaton MD, MBA, MBS, Sohrab Singh MD, Dhairya Nanavaty MD, Alexis K. Okoh MD, Srinivas Kesanakurthy MD, Rajiv Tayal MD, MPH
doi : 10.1002/ccd.30595
We analyzed the impact of frailty on readmission rates for ST-elevated myocardial infarctions (STEMIs) and the utilization of percutaneous coronary intervention (PCI) in STEMI admissions.
Early healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: The SORT-OUT VIII OCT study
Lene N. Andreasen MD, Ida R. Balleby MD, Trine Ø. Barkholt MD, PhD, Lasse Hebsgaard MD, Christian J. Terkelsen MD, DMSci, Emil N. Holck MD, Lisette O. Jensen MD, DMSci, Michael Maeng MD, PhD, Jouke Dijkstra PhD, Lisbeth Antonsen MD, PhD, Steen D. Kristensen MD, DMSci, Shengxian Tu DMSci, Jens F. Lassen MD, PhD, Evald H. Christiansen MD, PhD, Niels R. Holm MD
doi : 10.1002/ccd.30579
Early healing after drug-eluting stent (DES) implantation may reduce the risk of stent thrombosis. The aim of this study was to compare patterns of early healing after implantation of the thin strut everolimus-eluting Synergy DES (Boston Scientific) or the biolimus-eluting Biomatix Neoflex DES (Biosensors).
Cutting balloon to optimize predilation for stent implantation: The COPS randomized trial
Antonio Mangieri MD, Roberto Nerla MD, Fausto Castriota MD, Bernhard Reimers MD, Damiano Regazzoli MD, Pier P. Leone MD, Gabriele L. Gasparini MD, Arif A. Khokhar BM, BCh, Alessandra Laricchia MD, Francesco Giannini MD, Fulvio Casale MD, Andrea Bezzeccheri MD, Carlo Briguori MD, PhD, Antonio Colombo MD
doi : 10.1002/ccd.30603
The objective of this study is to investigate the use of cutting balloon (CB) inflated at high pressure compared with noncompliant balloon (NCB) for the treatment of calcified coronary lesions.
The impact of chronic total occlusions in patients undergoing transcatheter aortic valve replacement: A systematic review and meta-analysis
Maximilian Will MD, Konstantin Schwarz MD, PhD, Thomas Weiss MD, PhD, Gregor Leibundgut MD, Gudrun Lamm MD, Paul Vock MD, MSc, Julia Mascherbauer MD, Chun Shing Kwok MD, MSc, PhD
doi : 10.1002/ccd.30601
Coronary artery disease (CAD) is frequently encountered in patients evaluated for transcatheter aortic valve replacement (TAVR) due to severe aortic stenosis. The prognostic relevance of chronic total occlusions (CTOs) in this setting is poorly understood.
3D Printing-guided endovascular repair of enormous twisted thoracoabdominal aortic aneurysm with branch stenosis and occlusion
Wen-Dong Li MD, PhD, Reyaguli Keyoumu MD, Chao Wang PhD, Zhao Liu MD, PhD
doi : 10.1002/ccd.30578
A 67-year-old male patient was admitted with an enormous twisted thoracoabdominal aortic aneurysm (TAAA) with multiple branch arteries stenosis and occlusion.
Outcomes with plug-based versus suture-based vascular closure device after transfemoral transcatheter aortic valve replacement: A systematic review and meta-analysis
Ramy Sedhom MD, Alexander T. Dang MD, Amr Elwagdy MD, Michael Megaly MD, Islam Y. Elgendy MD, Firas Zahr MD, Samir Gafoor MD, Mamas Mamas MD, Ayman Elbadawi MD
doi : 10.1002/ccd.30597
Studies comparing plug-based (i.e., MANTA) with suture-based (i.e., ProStar XL and ProGlide) vascular closure devices (VCDs) for large-bore access closure after transcatheter aortic valve replacement (TAVR) have yielded mixed results.
Better together? Maybe not with CTO-PCI
Arnold H. Seto MD, MPA, David M. Tehrani MD, MS
doi : 10.1002/ccd.30606
Can patients be selected for transcatheter edge-to-edge repair based on the baseline transmitral gradient?
Hiroki Ueyama MD, Peter C. Block MD, FACC, MSCAI
doi : 10.1002/ccd.30607
A tale of two registries: Trends and outcomes of percutaneous coronary intervention in two transatlantic populations
Aaron Lee MD, Ian C. Gilchrist MD, MSCAI
doi : 10.1002/ccd.30608
Regulators can we get DCB balloons approved for use in the United States?
Richard R. Heuser MD, FACC, FACP, FESC, MSCAI
doi : 10.1002/ccd.30610
